Skip to main content
Evidence Snapshot

Angiotensin-converting enzyme

CHEMBL1808 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1808
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Angiotensin-converting enzyme as ChEMBL target CHEMBL1808, mapped to UniProt P12821. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Angiotensin-converting enzyme
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1808
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P12821
Angiotensin-converting enzyme
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Angiotensin-converting enzyme matters

As of 2026-09-14

Angiotensin-converting enzyme is reviewed as Angiotensin-converting enzyme (UniProt P12821); Angiotensin-converting enzyme shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block.; 14 linked drugs keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 1116 compounds, and 249 assays, with lead potency reaching pChEMBL 10.8.

Disease context
hypertension

Angiotensin-converting enzyme shows approved-linked disease relevance led by hypertension. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BENAZEPRIL HYDROCHLORIDE, CAPTOPRIL, DELAPRIL.

Start review with hypertension because it currently carries approved-linked support. Linked drugs include BENAZEPRIL HYDROCHLORIDE, CAPTOPRIL, DELAPRIL, ENALAPRIL MALEATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 14 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 1116 compounds, and 249 assays for this target. The dominant activity type is IC50. CHEMBL289556 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL289556 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Angiotensin-converting enzyme matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P12821, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hypertension is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1116
Total Compounds
249
Total Assays
18
Approved Drugs
IC50: 900.0, KI: 141.0, EC50: 3.0, KD: 27.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL289556
 10.8 Ki Clinical
No preferred name
CHEMBL443353
 10.5 IC50 —
No preferred name
CHEMBL1237
 10.0 IC50 Approved
No preferred name
CHEMBL289556
 10.0 IC50 Clinical
No preferred name
CHEMBL198316
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
TRANDOLAPRIL
CHEMBL1519
 1996
MOEXIPRIL
CHEMBL1165
 1995
LOSARTAN
CHEMBL191
 1995
PERINDOPRIL
CHEMBL1581
 1993
FOSINOPRIL
CHEMBL3039598
 1991
BENAZEPRIL
CHEMBL838
 1991
RAMIPRIL
CHEMBL1168
 1991
QUINAPRIL
CHEMBL1592
 1991
ENALAPRILAT ANHYDROUS
CHEMBL577
 1988
LISINOPRIL ANHYDROUS
CHEMBL1237
 1987
ENALAPRIL
CHEMBL578
 1985
CAPTOPRIL
CHEMBL1560
 1981
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1808